Drugmakers Increase Prices on Over 250 Medications
Key Points: 1. Over 250 branded drugs saw price increases in the U.S., including Paxlovid and cancer therapies. 2. Median ...
Tag: cancer
Ivonescimab improves survival in advanced non-small cell lung cancer
1. Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the pembrolizumab group. 2. Grade ...
#VisualAbstract: Reduced-Dose Apixaban was Noninferior to Full-Dose for Cancer-Associated Venous Thromboembolism
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Sotorasib plus panitumumab may be a promising treatment option for colorectal cancer
1. While not statistically significant, the use of sotorasib plus panitumumab may have a 30% relative risk reduction in the ...
Genetic, clinical, lifestyle and sociodemographic risk factors for head and neck cancer:
1. The highest-ranking phenotypic predictors of head and neck cancer included past tobacco smoking, job code at baseline, pain experienced ...
Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer
1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events ...
Less frequent mammography is non-inferior to annual screening for breast cancer survival in women after curative treatment
1. 5-year breast cancer-specific survival was comparable between annual and less frequent mammography groups. 2. Less-frequent mammographic surveillance showed a ...
#VisualAbstract Lack of sentinel-lymph node biopsy does not alter survival in early invasive breast cancer
1. In this randomized, non-inferiority trial, the omission of surgical axillary staging was noninferior to sentinel lymph node biopsy in patients ...
Endometriosis and Uterine Fibroids Associated with a Greater Risk of Mortality due to Gynecologic Cancers
1. A history of endometriosis and uterine fibroids in women was associated with a greater risk of premature mortality ...
Bristol Myers Squibb: Opdivo-Qvantig is the first FDA approved subcutaneous version of cancer immunotherapy targeting PD-1
Opdivo-Qvantig had a non-inferior objective response rate compared to intravenous formulation in patients with locally advanced or metastatic clear cell ...